Provided by Tiger Trade Technology Pte. Ltd.

Savara Inc

6.43
-0.1800-2.72%
Volume:9.20M
Turnover:60.08M
Market Cap:1.31B
PE:-12.02
High:6.75
Open:6.52
Low:6.42
Close:6.61
52wk High:7.01
52wk Low:1.89
Shares:203.47M
Float Shares:115.00M
Volume Ratio:1.99
T/O Rate:8.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5350
EPS(LYR):-0.4838
ROE:-78.74%
ROA:-39.67%
PB:13.86
PE(LYR):-13.29

Loading ...

Savara Announces Encore Presentations of Results From the Phase 3 Impala-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (Apap) at Chest 2025

THOMSON REUTERS
·
Oct 03

Savara Inc. Announces Positive Phase 3 Results for Molgramostim in aPAP, Highlighting Consistent Efficacy Across Disease Severities at ERS Congress 2025

Reuters
·
Sep 29

Savara Presents New Data From the Phase 3 Impala-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (Apap) at the European Respiratory Society (Ers) Congress 2025

THOMSON REUTERS
·
Sep 29

Savara Inc. Faces Legal Battle Over MOLBREEVI Controversy

TIPRANKS
·
Sep 12

Savara Is Maintained at Buy by Guggenheim

Dow Jones
·
Sep 09

Oppenheimer Adjusts Savara Price Target to $8 From $6, Maintains Outperform Rating

MT Newswires Live
·
Sep 08

Savara Is Maintained at Outperform by Oppenheimer

Dow Jones
·
Sep 08

U.S. RESEARCH ROUNDUP-Apple, Sanofi, Watts Water Technologies

Reuters
·
Sep 08

Savara Inc : Jefferies Raises Target Price to $10.5 From $8.5

THOMSON REUTERS
·
Sep 08

Savara Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Sep 03

Savara, Inc. : H.c. Wainwright Raises Target Price to $8 From $5

THOMSON REUTERS
·
Sep 03

Savara Inc. Announces New Analysis Revealing 50% Increase in Autoimmune PAP Prevalence and Advances Toward FDA Resubmission of MOLBREEVI

Reuters
·
Sep 02

BRIEF-New England Journal Of Medicine To Publish Results From Savara’S Phase 3 Impala-2 Clinical Trial In Autoimmune Pulmonary Alveolar Proteinosis

Reuters
·
Aug 21

Stock Track | Savara Inc. Soars 6.80% After-Hours on Announcement of NEJM Publication of Positive Phase 3 Trial Results

Stock Track
·
Aug 21

Stock Track | Savara Inc. Soars 6.80% After Hours on NEJM Publication of Positive Phase 3 Trial Results

Stock Track
·
Aug 21

Savara Inc. Announces Publication of Phase 3 IMPALA-2 Trial Results in NEJM, Highlighting Efficacy of Molgramostim for Autoimmune PAP

Reuters
·
Aug 21

New England Journal of Medicine (Nejm) to Publish Results From Savara’s Pivotal Phase 3 Impala-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune Pap)

THOMSON REUTERS
·
Aug 21

Savara Inc. Unveils New Data from Phase 3 IMPALA-2 Trial on Molgramostim for Autoimmune Pulmonary Alveolar Proteinosis at ERS Congress 2025

Reuters
·
Aug 18

Savara to Present New Data From the Phase 3 Impala-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (Apap) at the European Respiratory Society Congress 2025

THOMSON REUTERS
·
Aug 18

Savara Shares Rise After Upgrade From HC Wainwright

MT Newswires Live
·
Aug 16